Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Betamethasone sodium refers to the water-soluble ester forms of the synthetic glucocorticoid corticosteroid betamethasone, most commonly as betamethasone sodium phosphate. It is used primarily for its potent anti-inflammatory and immunosuppressive effects. Betamethasone acts by binding to intracellular glucocorticoid receptors, modulating gene expression to suppress pro-inflammatory cytokines and mediators. This results in reduced swelling, redness, itching, and allergic reactions. Betamethasone sodium is typically administered via injection (often as a combination with less soluble esters like acetate for both rapid and sustained action) or as soluble tablets for oral use. Indications include severe inflammatory conditions (such as asthma exacerbations), autoimmune diseases (like rheumatoid arthritis), dermatologic disorders, endocrine disorders (including adrenal insufficiency), gastrointestinal diseases (such as ulcerative colitis), hematologic disorders, neoplastic disease symptom management, ophthalmic diseases, renal diseases, rheumatic disorders, nervous system conditions such as multiple sclerosis flares or cerebral edema prevention in certain settings[3][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone sodium.